Topic Editors

Department of Mechanical & Aerospace Engineering, The George Washington University, Washington, DC 20052, USA
Department of Mechanical and Aerospace Engineering, George Washington University, Washington, DC 20052, USA
Department of Mechanical & Aerospace Engineering, The George Washington University, Washington, DC 20052, USA

Advances in Low-Temperature Plasma Cancer Therapy

Abstract submission deadline
closed (20 June 2024)
Manuscript submission deadline
closed (20 September 2024)
Viewed by
1200

Topic Information

Dear Colleagues,

This topic will cover the most recent topics in the field of plasma cancer therapy. In the past two decades, low-temperature plasma cancer therapy has been proven to reflect promising effectiveness on many types of cancer cells in vitro and in vivo. Selectivity was also discovered that the normal cells and cancer cells respond differently to the plasma which can be used to minimize the side effects of the treatment. However, new active ingredients are discovered such as the radiofrequency emissions from the plasma, proving that plasma therapy is still not a fully understand cocktail. Therefore, the dose of plasma therapy is still unknown. On the other hand, since the plasma exposure to the open air can be disturbed by the environmental condition such as humidity and the target status such as the distance, control methods were also developed for the plasma generators to stabilize the treatments. This also leads to new low-temperature plasma generators such as plasma jet arrays to cover a larger treatment area, flexible DBD patches, and discharge tubes relying on physical effects only. Therefore, the frontiers in this field are clear, and we expect the following topics will be discussed soon.

Prof. Dr. Michael Keidar
Dr. Li Lin
Dr. Dayun Yan
Topic Editors

Keywords

  • plasma medicine
  • low-temperature plasma
  • atmospheric plasma
  • reactive oxygen species
  • reactive nitrogen species
  • plasma jet
  • DBD
  • cancer therapy

Participating Journals

Journal Name Impact Factor CiteScore Launched Year First Decision (median) APC
Cancers
cancers
4.5 8.0 2009 16.3 Days CHF 2900
Catalysts
catalysts
3.8 6.8 2011 12.9 Days CHF 2700
Current Oncology
curroncol
2.8 3.3 1994 17.6 Days CHF 2200
Plasma
plasma
1.9 2.3 2018 22.9 Days CHF 1400
Sci
sci
- 4.5 2019 27.4 Days CHF 1200

Preprints.org is a multidiscipline platform providing preprint service that is dedicated to sharing your research from the start and empowering your research journey.

MDPI Topics is cooperating with Preprints.org and has built a direct connection between MDPI journals and Preprints.org. Authors are encouraged to enjoy the benefits by posting a preprint at Preprints.org prior to publication:

  1. Immediately share your ideas ahead of publication and establish your research priority;
  2. Protect your idea from being stolen with this time-stamped preprint article;
  3. Enhance the exposure and impact of your research;
  4. Receive feedback from your peers in advance;
  5. Have it indexed in Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.

Published Papers

There is no accepted submissions to this Topic at this moment.
Back to TopTop